Pyruvate Kinase Isoform M2 (PKM2) as a Possible Biomarker for Cancer

National University Hospital, Singapore

Overview

The purpose of this study is to determine if pyruvate kinase M2 (PKM2) can be used as a biomarker in cancer. Pyruvate kinase M2 is more elevated in malignant pleural fluid than in plasma, and may be a useful biomarker to distinguish between malignant and non-malignant causes of pleural effusion. In addition, pyruvate kinase M2 has also been found to be elevated in saliva in cancer patients compared to controls. Measuring pyruvate kinase M2 in saliva may be used to diagnose cancer or monitor the treatment progress of cancer.

Study Type

OBSERVATIONAL

Conditions

Cancer

Interventions

Pyruvate kinase isoform M2OTHER

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Any cancer patient with pleural effusion that is being drained through an indwelling chest-tube in an inpatient ward. Exclusion Criteria: * Patient with a pleural effusion who does not have proven cancer or whose pleural effusion is not known to be malignant.

Locations (1)

National University Hospital, Singapore

Singapore, Singapore

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.